298 related articles for article (PubMed ID: 34833868)
1. Thrombolytic Agents: Nanocarriers in Targeted Release.
Shen M; Wang Y; Hu F; Lv L; Chen K; Xing G
Molecules; 2021 Nov; 26(22):. PubMed ID: 34833868
[TBL] [Abstract][Full Text] [Related]
2. Advances in Nano-Functional Materials in Targeted Thrombolytic Drug Delivery.
Ren T; Mi Y; Wei J; Han X; Zhang X; Zhu Q; Yue T; Gao W; Niu X; Han C; Wei B
Molecules; 2024 May; 29(10):. PubMed ID: 38792186
[TBL] [Abstract][Full Text] [Related]
3. Liposomes for the delivery of streptokinase.
Kumar L; Verma S; Vaidya B
Ther Deliv; 2017 Oct; 8(10):855-866. PubMed ID: 28944736
[TBL] [Abstract][Full Text] [Related]
4. Novel and emerging therapies: thrombus-targeted fibrinolysis.
Lippi G; Mattiuzzi C; Favaloro EJ
Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
[TBL] [Abstract][Full Text] [Related]
5. Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies.
Pitek AS; Wang Y; Gulati S; Gao H; Stewart PL; Simon DI; Steinmetz NF
Mol Pharm; 2017 Nov; 14(11):3815-3823. PubMed ID: 28881141
[TBL] [Abstract][Full Text] [Related]
6. Long-circulating nanoparticles as passive targeting nanocarriers for the treatment of thrombosis.
Li J; Lu K; Sun S; Peng J; Zhao L
Nanoscale; 2024 Mar; 16(12):6132-6141. PubMed ID: 38444355
[TBL] [Abstract][Full Text] [Related]
7. Advanced drug delivery systems for antithrombotic agents.
Greineder CF; Howard MD; Carnemolla R; Cines DB; Muzykantov VR
Blood; 2013 Aug; 122(9):1565-75. PubMed ID: 23798715
[TBL] [Abstract][Full Text] [Related]
8. Thrombolytic Agents: Nanocarriers in Controlled Release.
Hassanpour S; Kim HJ; Saadati A; Tebon P; Xue C; van den Dolder FW; Thakor J; Baradaran B; Mosafer J; Baghbanzadeh A; de Barros NR; Hashemzaei M; Lee KJ; Lee J; Zhang S; Sun W; Cho HJ; Ahadian S; Ashammakhi N; Dokmeci MR; Mokhtarzadeh A; Khademhosseini A
Small; 2020 Oct; 16(40):e2001647. PubMed ID: 32790000
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy.
McCarthy JR; Sazonova IY; Erdem SS; Hara T; Thompson BD; Patel P; Botnaru I; Lin CP; Reed GL; Weissleder R; Jaffer FA
Nanomedicine (Lond); 2012 Jul; 7(7):1017-28. PubMed ID: 22348271
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of thrombolytic agents: role of integrin receptors.
Vyas SP; Vaidya B
Expert Opin Drug Deliv; 2009 May; 6(5):499-508. PubMed ID: 19413457
[TBL] [Abstract][Full Text] [Related]
11. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis.
Marsh JN; Senpan A; Hu G; Scott MJ; Gaffney PJ; Wickline SA; Lanza GM
Nanomedicine (Lond); 2007 Aug; 2(4):533-43. PubMed ID: 17716136
[TBL] [Abstract][Full Text] [Related]
12. Application of Nanotechnology in Thrombus Therapy.
Zhou S; Zhao W; Hu J; Mao C; Zhou M
Adv Healthc Mater; 2023 Mar; 12(7):e2202578. PubMed ID: 36507827
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke.
Zamanlu M; Farhoudi M; Eskandani M; Mahmoudi J; Barar J; Rafi M; Omidi Y
J Drug Target; 2018 Feb; 26(2):95-109. PubMed ID: 28796540
[TBL] [Abstract][Full Text] [Related]
14. Thrombus-specific theranostic nanocomposite for codelivery of thrombolytic drug, algae-derived anticoagulant and NIR fluorescent contrast agent.
Chang LH; Chuang EY; Cheng TM; Lin C; Shih CM; Wu AT; Jheng PR; Lu HY; Shih CC; Mi FL
Acta Biomater; 2021 Oct; 134():686-701. PubMed ID: 34358695
[TBL] [Abstract][Full Text] [Related]
15. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
Chen HA; Ma YH; Hsu TY; Chen JP
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917
[TBL] [Abstract][Full Text] [Related]
16. [Preparation of thrombus-targeted urokinase liposomes and its thrombolytic effect in model rats].
Wang XT; Li S; Zhang XB; Hou XP
Yao Xue Xue Bao; 2003 Mar; 38(3):231-5. PubMed ID: 12830724
[TBL] [Abstract][Full Text] [Related]
17. Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy.
Absar S; Nahar K; Kwon YM; Ahsan F
Pharm Res; 2013 Jun; 30(6):1663-76. PubMed ID: 23468049
[TBL] [Abstract][Full Text] [Related]
18. Self-Assembling Drug Formulations with Tunable Permeability and Biodegradability.
Gaynanova G; Vasileva L; Kashapov R; Kuznetsova D; Kushnazarova R; Tyryshkina A; Vasilieva E; Petrov K; Zakharova L; Sinyashin O
Molecules; 2021 Nov; 26(22):. PubMed ID: 34833877
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of site specific target sensitive liposomes for the delivery of thrombolytic agents.
Vaidya B; Nayak MK; Dash D; Agrawal GP; Vyas SP
Int J Pharm; 2011 Jan; 403(1-2):254-61. PubMed ID: 20971175
[TBL] [Abstract][Full Text] [Related]
20. Catheter-based local thrombolysis with urokinase: comparative efficacy of intraluminal clot lysis with conventional urokinase infusion techniques in an in vivo porcine thrombus model.
Mitchel JF; Shwedick M; Alberghini TA; Knibbs D; McKay RG
Cathet Cardiovasc Diagn; 1997 Jul; 41(3):293-302. PubMed ID: 9213028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
